BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30509093)

  • 1. Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors.
    Ohnona J; Nataf V; Gauthe M; Balogova S; Belissant Benesty O; Zhang-Yin J; Talbot JN; Montravers F
    Neoplasma; 2019 Jan; 66(1):140-148. PubMed ID: 30509093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas.
    Ambrosini V; Campana D; Polverari G; Peterle C; Diodato S; Ricci C; Allegri V; Casadei R; Tomassetti P; Fanti S
    J Nucl Med; 2015 Dec; 56(12):1843-8. PubMed ID: 26405169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
    Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
    Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of a whole-body dynamic 68GA-DOTATOC PET/CT acquisition to differentiate physiological uptake of pancreatic uncinate process from pancreatic neuroendocrine tumor.
    Thuillier P; Bourhis D; Karakatsanis N; Schick U; Metges JP; Salaun PY; Kerlan V; Abgral R
    Medicine (Baltimore); 2020 Aug; 99(33):e20021. PubMed ID: 32871968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
    Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
    Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (
    Matsumoto T; Okabe H; Yamashita YI; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
    Surg Today; 2019 Jan; 49(1):21-26. PubMed ID: 30128759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.
    Acker G; Kluge A; Lukas M; Conti A; Pasemann D; Meinert F; Anh Nguyen PT; Jelgersma C; Loebel F; Budach V; Vajkoczy P; Furth C; Baur ADJ; Senger C
    Neurosurg Focus; 2019 Jun; 46(6):E9. PubMed ID: 31153151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 68Ga-DOTATOC and 18F-FDG PET Predicts a Double Component With Different Grade of a Pancreatic Neuroendocrine Tumor in a Patient With Multiple Endocrine Neoplasia Type 1.
    Paepegaey AC; Gaujoux S; Meyer C; Rouquette A; Libé R
    Clin Nucl Med; 2020 Jun; 45(6):e281-e282. PubMed ID: 32349092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from
    Thuillier P; Liberini V; Grimaldi S; Rampado O; Gallio E; Santi B; Arvat E; Piovesan A; Filippi R; Abgral R; Molinari F; Deandreis D
    J Nucl Med; 2022 Jul; 63(7):1014-1020. PubMed ID: 34740949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT and 68Ga-DOTATOC PET/CT in Diffuse Pancreatic Neuroendocrine Tumor.
    Ji X; Dong A; He Q; Dong H; Zuo C
    Clin Nucl Med; 2020 May; 45(5):e245-e248. PubMed ID: 32049733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Luboldt W; Hartmann H; Wiedemann B; Zöphel K; Luboldt HJ
    Mol Imaging; 2010 Dec; 9(6):351-8. PubMed ID: 21084031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
    Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
    J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.